Teva Pharmaceutical Industries (TEVA) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Teva Pharmaceutical Industries (NYSE: TEVA):

• 1/21/2026 – Teva Pharmaceutical Industries had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/18/2026 – Teva Pharmaceutical Industries was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 1/10/2026 – Teva Pharmaceutical Industries was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/6/2026 – Teva Pharmaceutical Industries had its price target raised by analysts at Jefferies Financial Group Inc. from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an “overweight” rating on the stock.
• 12/19/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an “overweight” rating on the stock.
• 12/13/2025 – Teva Pharmaceutical Industries was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/9/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at Bank of America Corporation from $29.00 to $32.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Teva Pharmaceutical Industries is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $35.00 price target on the stock.
• 12/8/2025 – Teva Pharmaceutical Industries was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
• 12/8/2025 – Teva Pharmaceutical Industries had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a “buy” rating on the stock.
• 12/5/2025 – Teva Pharmaceutical Industries is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $35.00 price target on the stock.

Insider Buying and Selling

In related news, Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 622,060 shares of company stock valued at $17,076,965. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.